Jaguar Health shares closed at $0.82 on Monday, 2 November, their lowest close in a year and 49.4% below the previous 52-week low of $1.62 set on 30 October 2026. The shares have fallen 99.9% over the past year, excluding dividends.
Jaguar Health's share price over the year
The 52-week closing range ran from $1.62 to $1,040. Over longer periods the shares are down 100.0% over three years and down 100.0% over five years, excluding dividends.
The free-cash-flow margin of −24.0% is above every past reading in the company's own record, which ran from −10258.4% to −25.5%
What stands out is that revenue growth is slowing. Revenue over the twelve months to Q2 2026 was $27.8 million, up 135.5% on the year before, but that rate was 20.4 percentage points below the rate a quarter earlier.
Margins are improving from a year ago. The trailing operating margin of −93.1% is up 185.0 percentage points from a year earlier, yet the trailing net margin of −188.5% means the company made a net loss of $52.4 million over the twelve months. The trailing gross margin of 82.3% is consumed by operating costs.
Operating cash flow over the twelve months was −$6.7 million.
The free-cash-flow margin of −24.0% is above every past quarterly reading in the company's own record, which has ranged from −10258.4% to −25.5%.
Where Jaguar Health's figures sit in its own record
The company's own record places the remaining figures in context. The operating margin of −93.1% is higher than 97% of past readings, which span from −9599.8% to −89.0%. Revenue growth of 135.5% is higher than 67% of past readings, which range from −45.2% to 2981.6%.
What Jaguar Health's next report has to show
A 52-week low marks where the price has ended, not why it got there. The next results will show whether the trends in the filings above hold.